uracil has been researched along with HIV Coinfection in 38 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co-infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation." | 7.85 | Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. ( But, DY; Chan, CK; Chan, HL; Chan, KH; Fung, J; Hui, YT; Lai, CL; Lai, MS; Lam, YS; Lao, WC; Li, C; Lui, GC; Seto, WK; Tsang, OT; Wong, GL; Wong, VW; Yuen, MF, 2017) |
| " However, evening atazanavir plus ritonavir and lopinavir/ritonavir regimens are not recommended in combination with the 3D regimen." | 6.82 | Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. ( Awni, W; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Wang, H, 2016) |
| "We conducted a nonrandomized clinical trial of 12 or 24 weeks of paritaprevir-ritonavir-ombitasvir plus dasabuvir (PrOD) with or without ribavirin in persons with HCV-1/HIV coinfection suppressed with antiretroviral therapy." | 5.34 | Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation. ( Alston-Smith, BL; Anthony, DD; Balagopal, A; Bhattacharya, D; Cohen, DE; Damjanovska, S; Kowal, CM; Shive, CL; Smeaton, LM; Sulkowski, MS; Wyles, DL, 2020) |
| "AbbVie's 3 direct-acting antiviral (3D) regimen containing ombitasvir, paritaprevir, ritonavir, and dasabuvir with and without ribavirin is approved for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection." | 4.95 | Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse. ( King, JR; Menon, RM, 2017) |
| "A fixed-dose tablet comprising ombitasvir (an NS5A replication complex inhibitor), paritaprevir (an NS3/4A protease inhibitor) and ritonavir (a cytochrome P450 inhibitor) taken in combination with dasabuvir (an NS5B polymerase inhibitor) is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection in several countries, including the USA (copackaged as Viekira Pak(™)) and those of the EU (Viekirax(®) and Exviera(®))." | 4.91 | Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection. ( Deeks, ED, 2015) |
| "Among 41 patients treated, 35 (85%) patients had genotype 1b HCV infection, 6 (15%) had co-infection with human immunodeficiency virus, 35 (85%) failed previous peginterferon and ribavirin therapy, 25 (61%) had compensated liver cirrhosis, and 3 (7%) had liver transplantation." | 3.85 | Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. ( But, DY; Chan, CK; Chan, HL; Chan, KH; Fung, J; Hui, YT; Lai, CL; Lai, MS; Lam, YS; Lao, WC; Li, C; Lui, GC; Seto, WK; Tsang, OT; Wong, GL; Wong, VW; Yuen, MF, 2017) |
| "The combination of ombitasvir, dasabuvir, and paritaprevir/ritonavir (considered as the 3D regimen) has proven to be associated with high sustained virologic response and optimal tolerability in hepatitis C virus-infected patients." | 3.83 | Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction. ( Cattaneo, D; Clementi, E; Gervasoni, C; Milazzo, L; Riva, A, 2016) |
| " However, evening atazanavir plus ritonavir and lopinavir/ritonavir regimens are not recommended in combination with the 3D regimen." | 2.82 | Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors. ( Awni, W; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Wang, H, 2016) |
| " These data indicate that the 3-direct-acting-antiviral regimen can be administered with dolutegravir or abacavir plus lamivudine without dose adjustment." | 2.82 | Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine. ( Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Zhao, W, 2016) |
| "Uracil in DNA is a deleterious event that may arise either by cytosine deamination or misincorporation of dUTP." | 2.43 | Uracils as a cellular weapon against viruses and mechanisms of viral escape. ( Priet, S; Quérat, G; Sire, J, 2006) |
| "7%): 4 due to severe adverse events (including 3 deaths) and 1 patient´s decision." | 1.51 | Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study. ( Ahumada, A; Aldamiz-Echevarría, T; Baliellas, C; Barril, G; Benlloch, S; Bonet, L; Carmona, I; Castaño, MA; Castro, Á; de Álvaro, C; de Los Santos, I; Delgado, M; Devesa-Medina, MJ; García-Buey, L; García-Samaniego, J; Gea-Rodríguez, F; González-Parra, E; Gutiérrez, ML; Jiménez-Pérez, M; Laguno, M; Londoño, MC; Losa, JE; Mallolas, J; Manzanares, A; Martín-Granizo, I; Montero-Alonso, M; Montes, ML; Morán-Sánchez, S; Morano, L; Muñoz-Gómez, R; Navascués, CA; Polo-Lorduy, B; Riveiro-Barciela, M; Rivero, A; Roget, M; Serra, MÁ, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (13.16) | 18.2507 |
| 2000's | 2 (5.26) | 29.6817 |
| 2010's | 25 (65.79) | 24.3611 |
| 2020's | 6 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Gaidai, EA | 1 |
| Kryshen, KL | 1 |
| Jain Korsakova, EA | 1 |
| Demchenko, DV | 1 |
| Kargopol'tseva, DR | 1 |
| Katel'nikova, AE | 1 |
| Gaidai, DS | 1 |
| Balabanyan, VY | 1 |
| Cui, J | 2 |
| Meshesha, M | 2 |
| Churgulia, N | 2 |
| Merlo, C | 1 |
| Fuchs, E | 1 |
| Breakey, J | 1 |
| Jones, J | 1 |
| Stivers, JT | 3 |
| Londoño, MC | 1 |
| Riveiro-Barciela, M | 1 |
| Ahumada, A | 1 |
| Muñoz-Gómez, R | 1 |
| Roget, M | 1 |
| Devesa-Medina, MJ | 1 |
| Serra, MÁ | 1 |
| Navascués, CA | 1 |
| Baliellas, C | 1 |
| Aldamiz-Echevarría, T | 2 |
| Gutiérrez, ML | 1 |
| Polo-Lorduy, B | 2 |
| Carmona, I | 1 |
| Benlloch, S | 1 |
| Bonet, L | 1 |
| García-Samaniego, J | 1 |
| Jiménez-Pérez, M | 1 |
| Morán-Sánchez, S | 2 |
| Castro, Á | 1 |
| Delgado, M | 3 |
| Gea-Rodríguez, F | 1 |
| Martín-Granizo, I | 2 |
| Montes, ML | 1 |
| Morano, L | 2 |
| Castaño, MA | 1 |
| de Los Santos, I | 2 |
| Laguno, M | 1 |
| Losa, JE | 1 |
| Montero-Alonso, M | 1 |
| Rivero, A | 2 |
| de Álvaro, C | 1 |
| Manzanares, A | 2 |
| Mallolas, J | 1 |
| Barril, G | 1 |
| González-Parra, E | 1 |
| García-Buey, L | 2 |
| Manuel Sousa, J | 1 |
| Vergara, M | 1 |
| Pulido, F | 1 |
| Sánchez Antolín, G | 1 |
| Hijona, L | 1 |
| Carnicer, F | 1 |
| Rincón, D | 1 |
| Salmerón, J | 1 |
| Mateos-Muñoz, B | 1 |
| Jou, A | 1 |
| Rubín, Á | 1 |
| Escarda, A | 1 |
| Aguilar, P | 1 |
| Carrión, JA | 1 |
| Hernández-Guerra, M | 1 |
| Chimeno-Hernández, S | 1 |
| Espinosa, N | 1 |
| Morillas, RM | 1 |
| Andrade, RJ | 1 |
| Gallego, A | 1 |
| Magaz, M | 1 |
| Moreno-Planas, JM | 1 |
| Estébanez, Á | 1 |
| Rico, M | 1 |
| Menéndez, F | 1 |
| Sampedro, B | 1 |
| Izquierdo, S | 1 |
| Zozaya, JM | 1 |
| Rodríguez, M | 1 |
| Lorente, S | 1 |
| Von-Wichmann, MÁ | 1 |
| Guaraldi, G | 1 |
| Maurice, JB | 1 |
| Marzolini, C | 1 |
| Monteith, K | 1 |
| Milic, J | 1 |
| Tsochatzis, E | 1 |
| Bhagani, S | 1 |
| Morse, CG | 1 |
| Price, JC | 1 |
| Ingiliz, P | 1 |
| Lemoine, M | 1 |
| Sebastiani, G | 1 |
| Anthony, DD | 1 |
| Sulkowski, MS | 1 |
| Smeaton, LM | 1 |
| Damjanovska, S | 1 |
| Shive, CL | 1 |
| Kowal, CM | 1 |
| Cohen, DE | 1 |
| Bhattacharya, D | 1 |
| Alston-Smith, BL | 1 |
| Balagopal, A | 1 |
| Wyles, DL | 1 |
| Esadze, A | 1 |
| Sahu, SK | 1 |
| Geant, PY | 1 |
| Uttaro, JP | 1 |
| Périgaud, C | 1 |
| Mathé, C | 1 |
| Tempestilli, M | 1 |
| Fabbri, G | 1 |
| Mastrorosa, I | 1 |
| Timelli, L | 1 |
| Notari, S | 1 |
| Bellagamba, R | 1 |
| Libertone, R | 1 |
| Lupi, F | 1 |
| Zaccarelli, M | 1 |
| Antinori, A | 2 |
| Agrati, C | 1 |
| Ammassari, A | 1 |
| Pineda, JA | 1 |
| Rivero-Juárez, A | 1 |
| Collado, A | 1 |
| Merino, D | 1 |
| Morano-Amado, LE | 1 |
| Ríos, MJ | 1 |
| Pérez-Pérez, M | 1 |
| Téllez, F | 1 |
| Palacios, R | 1 |
| Pérez, AB | 1 |
| Mancebo, M | 1 |
| Macías, J | 1 |
| Taramasso, L | 1 |
| Di Biagio, A | 1 |
| Bovis, F | 1 |
| Nicolini, LA | 1 |
| Milazzo, L | 4 |
| Sollima, S | 4 |
| Gubertini, G | 1 |
| Niero, F | 1 |
| Saracino, A | 1 |
| Bruno, R | 1 |
| Borghi, V | 1 |
| Montagnani, F | 1 |
| Cattelan, A | 1 |
| Hasson, H | 1 |
| Taliani, G | 1 |
| D'Arminio Monforte, A | 1 |
| Mastroianni, C | 1 |
| Di Perri, G | 1 |
| Bigoni, S | 1 |
| Puoti, M | 1 |
| Spinetti, A | 1 |
| Gori, A | 1 |
| Boffa, N | 1 |
| Cacopardo, B | 1 |
| Giacometti, A | 1 |
| Parruti, G | 1 |
| Vullo, V | 1 |
| Chirianni, A | 1 |
| Teti, E | 1 |
| Pasquazzi, C | 1 |
| Segala, D | 1 |
| Andreoni, M | 1 |
| Saragani, Y | 1 |
| Hizi, A | 1 |
| Rahav, G | 1 |
| Zaouch, S | 1 |
| Bakhanashvili, M | 1 |
| Wu, J | 1 |
| Huang, P | 1 |
| Fan, H | 1 |
| Tian, T | 1 |
| Xia, X | 1 |
| Fu, Z | 1 |
| Wang, Y | 1 |
| Ye, X | 1 |
| Yue, M | 1 |
| Zhang, Y | 1 |
| Venter, WDF | 1 |
| Moorhouse, M | 1 |
| Sokhela, S | 1 |
| Fairlie, L | 1 |
| Mashabane, N | 1 |
| Masenya, M | 1 |
| Serenata, C | 1 |
| Akpomiemie, G | 1 |
| Qavi, A | 1 |
| Chandiwana, N | 1 |
| Norris, S | 1 |
| Chersich, M | 1 |
| Clayden, P | 1 |
| Abrams, E | 1 |
| Arulappan, N | 1 |
| Vos, A | 1 |
| McCann, K | 1 |
| Simmons, B | 1 |
| Hill, A | 1 |
| Putz, MV | 2 |
| Dudaş, NA | 2 |
| Deeks, ED | 1 |
| Isvoran, A | 1 |
| Cattaneo, D | 3 |
| Charbe, N | 1 |
| Resnati, C | 1 |
| Clementi, E | 2 |
| Gervasoni, C | 3 |
| Torre, A | 1 |
| Calvi, E | 1 |
| Regalia, E | 1 |
| Antinori, S | 1 |
| Cheng, EY | 1 |
| Saab, S | 2 |
| Holt, CD | 1 |
| Busuttil, RW | 1 |
| Khatri, A | 2 |
| Dutta, S | 1 |
| Wang, H | 1 |
| Podsadecki, T | 2 |
| Trinh, R | 2 |
| Awni, W | 1 |
| Menon, R | 2 |
| Riva, A | 1 |
| D'Avolio, A | 1 |
| Micheli, V | 1 |
| Virabhak, S | 1 |
| Parisé, H | 1 |
| Johnson, S | 1 |
| Wang, A | 1 |
| Misurski, D | 1 |
| Gonzalez, YS | 1 |
| Juday, T | 1 |
| Zhao, W | 1 |
| Hansen, EC | 1 |
| Ransom, M | 1 |
| Hesselberth, JR | 1 |
| Hosmane, NN | 1 |
| Capoferri, AA | 1 |
| Bruner, KM | 1 |
| Pollack, RA | 1 |
| Zhang, H | 1 |
| Drummond, MB | 1 |
| Siliciano, JM | 1 |
| Siliciano, R | 1 |
| Chan, HL | 1 |
| Tsang, OT | 1 |
| Hui, YT | 1 |
| Fung, J | 1 |
| Lui, GC | 1 |
| Lai, CL | 1 |
| Wong, GL | 1 |
| Chan, KH | 1 |
| But, DY | 1 |
| Lai, MS | 1 |
| Lao, WC | 1 |
| Chan, CK | 1 |
| Lam, YS | 1 |
| Seto, WK | 1 |
| Li, C | 1 |
| Yuen, MF | 1 |
| Wong, VW | 1 |
| Tang, J | 1 |
| Kirby, KA | 1 |
| Huber, AD | 1 |
| Casey, MC | 1 |
| Ji, J | 1 |
| Wilson, DJ | 1 |
| Sarafianos, SG | 1 |
| Wang, Z | 1 |
| King, JR | 1 |
| Menon, RM | 1 |
| Decha, P | 1 |
| Intharathep, P | 1 |
| Udommaneethanakit, T | 1 |
| Sompornpisut, P | 1 |
| Hannongbua, S | 1 |
| Wolschann, P | 1 |
| Parasuk, V | 1 |
| Li, S | 1 |
| Hattori, T | 1 |
| Kodama, EN | 1 |
| Priet, S | 1 |
| Sire, J | 1 |
| Quérat, G | 1 |
| Ijichi, K | 1 |
| Fujiwara, M | 1 |
| Shigeta, S | 1 |
| Konno, K | 1 |
| Yokota, T | 1 |
| Baba, M | 1 |
| Balzarini, J | 1 |
| Pelemans, H | 1 |
| Karlsson, A | 1 |
| De ClercQ, E | 1 |
| Kleim, JP | 1 |
| Jaruga, P | 1 |
| Jaruga, B | 1 |
| Olczak, A | 1 |
| Halota, W | 1 |
| Olinski, R | 1 |
| Crowe, S | 1 |
| Duval, X | 1 |
| Cheonis, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)[NCT02194998] | Phase 2 | 46 participants (Actual) | Interventional | 2015-09-16 | Terminated (stopped due to The study closed to accrual before the planned accrual goal was attained due to the availability of newer directly-acting antiviral (DAA) treatments for HCV.) | ||
| Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1[NCT04904406] | Phase 4 | 95 participants (Anticipated) | Interventional | 2020-10-22 | Recruiting | ||
| WRHI 060 (ADVANCE): A Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF + FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy - Extension to 192 Weeks[NCT03122262] | Phase 3 | 1,110 participants (Actual) | Interventional | 2017-01-16 | Completed | ||
| Can the Weight Gain Associated With Use of Integrase Strand Inhibitors be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF in Patients Living With HIV? (DeLiTE)[NCT04665375] | Phase 4 | 25 participants (Anticipated) | Interventional | 2021-04-26 | Enrolling by invitation | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
HIV-1 VF was defined as two consecutive HIV-1 RNA results ≥ 200 copies/mL. (NCT02194998)
Timeframe: From treatment initiation to 4 weeks after last dose of HCV study treatment. HIV-1 RNA was measured at weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, and 28. The durations for HCV study treatment for Cohorts A/C and Cohorts B/D were 24 and 12 weeks, respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 1 |
HCV VF was defined as follows: confirmed increase from nadir in HCV RNA (defined as two consecutive HCV RNA measurements of >1 log10 IU/mL above nadir) at any time point; failure to achieve HCV RNA
Timeframe: From treatment initiation to either 24 weeks (for Cohort A and C) or 12 weeks (for Cohort B and D). The duration for HCV study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 1 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 1 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
Participants who had diagnoses leading to premature HCV study treatment or HIV-1 ARV discontinuation post treatment initiation. (NCT02194998)
Timeframe: From treatment initiation to end of study follow-up at 48 weeks.The duration for HCV study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively. The duration for ARV treatment for all cohorts was 48 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 1 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
"Participants with an observed laboratory abnormalities grade 3 or higher post treatment initiation.~If entry (pre-treatment) lab result was grade 3, then a grade 4 result was required to meet this outcome.~Severity grading was based on DAIDS AE Grading Table, Version 1.0." (NCT02194998)
Timeframe: From treatment initiation to 30 days post date of last dose of HCV study treatment (whether planned or premature discontinuation). The duration for HCV study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 5 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 3 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 3 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
Participants who experienced at least one observed SAEs as defined by ICH after initiating HCV study treatment through 30 days post date of last dose of HCV study treatment. (NCT02194998)
Timeframe: From treatment initiation to 30 days post date of last dose of HCV study treatment (whether planned or premature discontinuation). The duration for HCV study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 1 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 1 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 2 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
"Participants with signs/symptoms of grade 3 or higher post treatment initiation.~Participants with grade 3 sign/symptom prior to treatment initiation must have had one grade higher than pre-treatment to meet this outcome.~Severity grading was based on DAIDS AE Grading Table, Version 1.0." (NCT02194998)
Timeframe: From treatment initiation to 30 days post date of last dose of HCV study treatment (whether planned or premature discontinuation). The duration for HCV study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 2 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 3 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
Participants with one or more genotype mutations in protease conferring major resistance to any HIV-1 Protease Inhibitors (PI) antiretroviral drug, from a plasma sample drawn following confirmed HIV-1 VF outcome. (NCT02194998)
Timeframe: At confirmation of HIV-1 virologic failure.
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 0 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 0 |
"SVR12 was defined as HCV RNA less than the assay LLOQ (<15 IU/mL) at 12 weeks post HCV treatment discontinuation.~A two-sided 90% confidence interval was calculated for the percentage of participants with SVR12 response using Clopper-Pearson method.~For those whose HCV early responses prior to SVR12 evaluation met the guidelines for HCV Virologic Failure (VF), their SVR12 outcome was defined as non-response. Those missing a HCV RNA result from the week 12 post HCV treatment discontinuation visit (and missing all subsequent evaluations) were considered non-responders. However, if HCV RNA evaluations subsequent to week 12 post treatment discontinuation were non-missing, then the first HCV RNA subsequent to week 12 post treatment discontinuation was instead used to define the primary outcome." (NCT02194998)
Timeframe: At 12 weeks after last dose of HCV study treatment. The duration for study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 95.2 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 60 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 100 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 100 |
"SVR24 was defined as HCV RNA less than the assay LLOQ (<15 IU/mL) at 24 weeks post treatment discontinuation.~A two-sided 90% confidence interval was calculated for the percentage of SVR24 response using method of Clopper-Pearson.~For those whose HCV early responses prior to SVR24 evaluation met the guidelines for HCV VF, their SVR24 outcome was defined as non-response. Those missing a HCV RNA result from the week 24 post HCV treatment discontinuation visit (and missing all subsequent evaluations) were considered non-responders. However, if HCV RNA evaluations subsequent to week 24 post treatment discontinuation were non-missing, then the first HCV RNA subsequent to week 24 post treatment discontinuation was instead used to define the primary outcome." (NCT02194998)
Timeframe: At 24 weeks after the date of last dose of HCV study treatment. The duration for study treatment for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 90.5 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 60 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 93.3 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 100 |
Absolute change from baseline in IP-10 (Interferon gamma-induced protein 10) concentration in plasma, calculated as value at the later time point minus baseline value. Baseline was defined as the date of first treatment dose. (NCT02194998)
Timeframe: At baseline, end of HCV treatment (EOT), and 12 weeks post EOT. The EOT for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | pg/mL (Median) | |
|---|---|---|
| Change from baseline to EOT | Change from baseline to 12 weeks post EOT | |
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | -244.4 | -127 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | -22.2 | -29.1 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | -116 | -83.1 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | -61.1 | -114.9 |
Absolute change from baseline in sCD14 levels in plasma calculated as value at the later time point minus baseline value. Baseline was defined as the date of first treatment dose. (NCT02194998)
Timeframe: At baseline, end of HCV treatment (EOT), and 12 weeks post EOT. The EOT for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | ng/mL (Median) | |
|---|---|---|
| Change from baseline to EOT | Change from baseline to 12 weeks post EOT | |
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 307.6 | 145.2 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | -1,063.2 | -894.2 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | -380.3 | -22.6 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 318.2 | -987.0 |
Levels of IP-10 (Interferon gamma-induced protein 10) concentration in plasma. Baseline was defined as the date of first treatment dose. (NCT02194998)
Timeframe: At baseline, end of HCV treatment (EOT), and 12 weeks post EOT. The EOT for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | pg/mL (Median) | ||
|---|---|---|---|
| IP-10 at baseline | IP-10 at EOT | IP-10 at 12 weeks post EOT | |
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 379 | 100.9 | 94.6 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 120.2 | 60.4 | 85.5 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 225.5 | 76.6 | 82.5 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 196.4 | 182.6 | 159.5 |
Levels of sCD14. Baseline was defined as the date of first treatment dose. (NCT02194998)
Timeframe: At baseline, end of HCV treatment (EOT), and 12 weeks post EOT. The EOT for Cohorts A and C and Cohorts B and D was 24 and 12 weeks, respectively.
| Intervention | ng/mL (Median) | ||
|---|---|---|---|
| sCD14 at Baseline | sCD14 at EOT | sCD14 at 12 weeks post EOT | |
| Cohort A [INI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 1,832.0 | 2,126.5 | 1,977.3 |
| Cohort B [INI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 2,226.8 | 1,132.8 | 1,367.4 |
| Cohort C [PI-based ART + PTV/r/OBT + DSV +/- RBV 24 Weeks] | 3,157.0 | 2,421.1 | 3,424.5 |
| Cohort D [PI-based ART + PTV/r/OBT + DSV +/- RBV 12 Weeks] | 3,092.0 | 2,801.3 | 2,608.3 |
4 reviews available for uracil and HIV Coinfection
| Article | Year |
|---|---|
Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance; Drug Resist | 2015 |
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
Topics: 2-Naphthylamine; Anilides; Anti-Retroviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Inte | 2017 |
Uracils as a cellular weapon against viruses and mechanisms of viral escape.
Topics: DNA, Viral; HIV Infections; HIV-1; Humans; Retroviridae; Uracil; Uracil-DNA Glycosidase; Virus Repli | 2006 |
New reverse transcriptase inhibitors.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Dideoxynucleosides; HIV Infections; HIV | 1999 |
6 trials available for uracil and HIV Coinfection
| Article | Year |
|---|---|
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Antiviral Agents; Biomarkers; Carbamates; Coinfec | 2020 |
Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; F | 2018 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Topics: Adenine; Adolescent; Adult; Anti-Retroviral Agents; Bone Density; CD4 Lymphocyte Count; Drug Therapy | 2019 |
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropan | 2016 |
Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Anti-Retroviral Agents; Carbamates; Cyclopropanes | 2016 |
Oxidative DNA base damage in lymphocytes of HIV-infected drug users.
Topics: Adenine; Adolescent; Adult; Chromatin; Cytosine; DNA Damage; Guanine; HIV Infections; Humans; Lympho | 1999 |
28 other studies available for uracil and HIV Coinfection
| Article | Year |
|---|---|
[Study of the specific toxic effects of the substance 1-[2-(2-benzoylphenoxy)ethyl]-6-methyluracil, the original non-nucleoside inhibitor of human immunodeficiency virus type 1 (Retroviridae; Orthoretrovirinae; Lentivirus: Human immunodeficiency virus 1)
Topics: Animals; Anti-HIV Agents; Guinea Pigs; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Len | 2021 |
Replication-competent HIV-1 in human alveolar macrophages and monocytes despite nucleotide pools with elevated dUTP.
Topics: DNA, Viral; HIV Infections; HIV-1; Humans; Macrophages, Alveolar; Monocytes; Nucleotides; SAM Domain | 2022 |
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Ther | 2019 |
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; F | 2019 |
New Drugs for NASH and HIV Infection: Great Expectations for a Great Need.
Topics: Anti-Retroviral Agents; Chalcones; Chenodeoxycholic Acid; Cholic Acids; Clinical Trials, Phase III a | 2020 |
Deficient uracil base excision repair leads to persistent dUMP in HIV proviruses during infection of monocytes and macrophages.
Topics: Deoxyuracil Nucleotides; DNA Repair; DNA, Viral; HIV Infections; HIV-1; Humans; Macrophages; Monocyt | 2020 |
Synthesis and Antiviral Evaluation of 3'-Fluoro-5'-norcarbocyclic Nucleoside Phosphonates Bearing Uracil and Cytosine as Potential Antiviral Agents.
Topics: Anti-HIV Agents; Cytosine; HIV Infections; HIV-1; Humans; Nucleosides; Organophosphonates; Structure | 2020 |
Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world.
Topics: 2-Naphthylamine; Anilides; Anti-Retroviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Inte | 2018 |
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients.
Topics: 2-Naphthylamine; Antiviral Agents; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filt | 2018 |
Cytoplasmic p53 contributes to the removal of uracils misincorporated by HIV-1 reverse transcriptase.
Topics: Cell Line, Tumor; Cytoplasm; DNA Damage; DNA Repair; DNA Replication; HIV Infections; HIV Reverse Tr | 2018 |
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Coinfectio | 2019 |
Determining chemical reactivity driving biological activity from SMILES transformations: the bonding mechanism of anti-HIV pyrimidines.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Molecular Structure; Monte Carlo Method; Quantitativ | 2013 |
Double Variational Binding--(SMILES) Conformational Analysis by Docking Mechanisms for Anti-HIV Pyrimidine Ligands.
Topics: Algorithms; Anti-HIV Agents; Binding Sites; Computational Biology; Drug Design; HIV Infections; Huma | 2015 |
Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Ther | 2016 |
Paritaprevir/ritonavir, ombitasvir, and dasabuvir for treatment of recurrent hepatitis C virus infection in the human immunodeficiency virus coinfected liver transplant recipient.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, C | 2016 |
Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinica | 2015 |
Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Atazanavir Sulfate; Carbamates; Coinfection; Cyclopropa | 2016 |
Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients.
Topics: 2-Naphthylamine; Anilides; Carbamates; Coinfection; Cyclopropanes; Darunavir; Hepatitis C; HIV Infec | 2016 |
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocel | 2016 |
Diverse fates of uracilated HIV-1 DNA during infection of myeloid lineage cells.
Topics: Cells, Cultured; DNA Repair; DNA, Viral; HIV Infections; HIV-1; Humans; Macrophages; Mutation; Rever | 2016 |
Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Administra | 2017 |
6-Cyclohexylmethyl-3-hydroxypyrimidine-2,4-dione as an inhibitor scaffold of HIV reverase transcriptase: Impacts of the 3-OH on inhibiting RNase H and polymerase.
Topics: Anti-HIV Agents; Binding Sites; Crystallization; HIV Infections; HIV Reverse Transcriptase; HIV-1; H | 2017 |
Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions.
Topics: Alkynes; Amino Acids; Benzoxazines; Binding Sites; Cyclopropanes; HIV Infections; HIV Reverse Transc | 2011 |
Epigallocatechin gallate inhibits the HIV reverse transcription step.
Topics: Anti-HIV Agents; Catechin; Drug Evaluation, Preclinical; Drug Synergism; HeLa Cells; HIV Infections; | 2011 |
Different properties of wild type and drug-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase in vitro.
Topics: Antiviral Agents; Cells, Cultured; DNA, Viral; Drug Resistance, Microbial; HIV Infections; HIV-1; Hu | 1996 |
Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.
Topics: Base Sequence; Cell Line; DNA Primers; Drug Administration Schedule; Drug Interactions; Drug Therapy | 1996 |
[The 39th ICAAC (San Francisco) and the 7th European Conference on Clinical Aspects and Treatment of HIV-infection (Lisbon). HIV infection: antiretroviral agents in the development and trial stage].
Topics: Alkynes; Animals; Anti-HIV Agents; Antiviral Agents; Benzoxazines; Clinical Trials as Topic; Cyclopr | 2000 |
Emivirine: an NRTI that functions as an NNRTI.
Topics: Anti-HIV Agents; Cesarean Section; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Mic | 1999 |